50 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
with the amendment for its internally developed products of a similar nature; provided that such amendment shall be
timely reported to the JSC … of a similar nature; provided that such amendment shall be timely reported to the JSC and/or Subcommittee for review, as appropriate, whereby Licensee shall
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
or omitted.
The unaudited interim condensed consolidated financial statements include adjustments of a normal recurring nature, as necessary … to be reasonable under the circumstances.
In preparing the interim condensed consolidated financial statements, the nature of significant judgments made
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
. Nature Reviews. Disease Primers. 2020. 6:74. https://doi.org/10.1038/s41572-020-0205-x Evaluate Pharma market data sourced in May 2023. Current
6-K
90lndj83 3bwt3gel
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
x1lafcxrebn
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
xvm ydqceqbf3l8lzh
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.2
y0mguuwfvozf7u3
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
EX-1.2
u74j4me
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
z5hq0d3279gmu3k4s65
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
EX-2.5
wh86622g kt
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
f4d e0f0ixjw36tu
31 Mar 22
Annual report (foreign)
4:33pm
20-F
2yq9zu18pfp2xph65bxs
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.10
4w6 myqswqjowiq5k0ka
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-1.1
7lj5rxy6akzoeymvdzdm
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.11
kq3qilbb4bx79z
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
g921usu ivfm2m
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
d77jqy4bq2fx2apqav
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
dfr923g4u13
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm